Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.
Current influenza virus vaccines protect mostly against homologous virus strains; thus, regular immunization with updated vaccine formulations is necessary to guard against the virus' hallmark remodeling of regions that mediate neutralization. Development of a broadly protective influenza vaccine would mark a significant advance in human infectious diseases research. Antibodies with broad neutralizing activity (nAbs) against multiple influenza virus strains or subtypes have been reported to bind the stalk of the viral hemagglutinin, suggesting that a vaccine based on this region could elicit a broadly protective immune response. Here we describe a hemagglutinin subunit 2 protein (HA2)-based synthetic peptide vaccine that provides protection in mice against influenza viruses of the structurally divergent subtypes H3N2, H1N1, and H5N1. The immunogen is based on the binding site of the recently described nAb 12D1, which neutralizes H3 subtype viruses, demonstrates protective activity in vivo, and, in contrast to a majority of described nAbs, appears to bind to residues within a single α-helical portion of the HA2 protein. Our data further demonstrate that the specific design of our immunogen is integral in the induction of broadly active anti-hemagglutinin antibodies. These results provide proof of concept for an HA2-based influenza vaccine that could diminish the threat of pandemic influenza disease and generally reduce the significance of influenza viruses as human pathogens.
Department of Microbiology and Medicine, Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Taia T
TT
Wang
Gene S
GS
Tan
Rong
R
Hai
Natalie
N
Pica
Lily
L
Ngai
Damian C
DC
Ekiert
Ian A
IA
Wilson
Adolfo
A
García-Sastre
Thomas M
TM
Moran
Peter
P
Palese
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology*; D000914:Antibodies, Viral / Q000276:immunology*; D006389:Hemagglutinins, Viral / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007114:Immunization; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology* / Q000517:prevention & control; D010455:Peptides / Q000276:immunology* / Q000494:pharmacology; D017433:Protein Structure, Secondary
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D010455:Peptides; C452559:hemagglutinin HA-2 fusogenic peptide, Influenza virus